research use only
Cat.No.S7911
| Related Targets | CXCR STING AhR Immunology & Inflammation related CD markers Interleukins Anti-infection Antioxidant COX Histamine Receptor |
|---|---|
| Other PD-1/PD-L1 Inhibitors | AUNP-12 BMS-202 PD-1/PD-L1 Inhibitor 3 BMS-1166 SR 0987 INCB086550 GS-4224 CA-170 (AUPM-170) BMS-1001 Sanguisorbae Radix Extract |
|
In vitro |
DMSO
: 95 mg/mL
(199.75 mM)
Water : 95 mg/mL Ethanol : 5 mg/mL |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 475.58 | Formula | C29H33NO5 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 1675201-83-8 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | PD-1/PD-L1 inhibitor 1 | Smiles | CC1=C(C=CC=C1C2=CC=CC=C2)COC3=CC(=C(C(=C3)OC)CN4CCCCC4C(=O)O)OC | ||
| Targets/IC50/Ki |
PD-1/PD-L1 interaction
(Cell-free assay) 0.006 μM
|
|---|---|
| In vitro |
PD-1/PD-L1 inhibitor 1 causes half-reduced cell viability at lower concentrations in triple-negative breast cancer (TNBC), activates ERK in MDA-MB-231 and MCF7, significantly increases IL-8 expression in MDA-MB-231 and HCC1806 when administrated in combination with ERK1/2 inhibitor, also potently downregulates the IL-8 expression to its half amount in MDA-MB-231. |
| In vivo |
PD-1/PD-L1 inhibitor 1 combined with Jiedu Sangen Decoction (JSD) remarkably inhibits and reverses epithelial-mesenchymal transition (EMT) via PI3K/AKT signaling pathway. |
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
Question 1:
I would like to know the difference of S8158, S7912, S7911, and the reason of why its IC50 is different.
Answer:
These three compounds are three different PD-l/PD-L1 inhibitors. It has a different structure, characteristic, and probably functions through a different mechanism. This is why the IC50s are different.